In a patient with hemophilia A with factor VIII at 35% preoperatively, which preoperative therapy is most appropriate to prepare for elective surgery?

In a patient with hemophilia A with factor VIII at 35% preoperatively, which preoperative therapy is most appropriate to prepare for elective surgery?

• A. Administer sufficient cryoprecipitate to raise factor VIII to 50%
• B. Administer sufficient factor VIII concentrate and platelets to raise to 50%
• C. Transfuse fresh frozen plasma until factor VIII is 100%
• D. Administer factor VIII concentrates until factor VIII is 100%

Answer: (D)

Hemophilia A causes a deficiency of factor VIII, so for elective surgery the goal is to restore normal coagulation by replacing the missing factor to a high, target level before the incision and during the operation. Using factor VIII concentrate achieves a precise, predictable rise in circulating FVIII (roughly a 2% increase in activity per IU/kg of concentrate), allowing you to bring the patient up to normal levels quickly and then maintain them with repeat dosing as needed. This targeted approach provides reliable hemostasis during surgery. In contrast, cryoprecipitate contains FVIII but in variable, less predictable amounts and also introduces other components, making dosing less reliable. Fresh frozen plasma would require large volumes to attempt the same rise and still may not achieve high FVIII levels promptly. Platelets do not correct the underlying FVIII deficiency and won’t raise circulating FVIII activity to normal levels. Therefore, administering factor VIII concentrates to achieve 100% activity is the most effective and safest preoperative strategy.

Hemophilia A causes a deficiency of factor VIII, so for elective surgery the goal is to restore normal coagulation by replacing the missing factor to a high, target level before the incision and during the operation. Using factor VIII concentrate achieves a precise, predictable rise in circulating FVIII (roughly a 2% increase in activity per IU/kg of concentrate), allowing you to bring the patient up to normal levels quickly and then maintain them with repeat dosing as needed. This targeted approach provides reliable hemostasis during surgery.

In contrast, cryoprecipitate contains FVIII but in variable, less predictable amounts and also introduces other components, making dosing less reliable. Fresh frozen plasma would require large volumes to attempt the same rise and still may not achieve high FVIII levels promptly. Platelets do not correct the underlying FVIII deficiency and won’t raise circulating FVIII activity to normal levels. Therefore, administering factor VIII concentrates to achieve 100% activity is the most effective and safest preoperative strategy.